Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older

BACKGROUND: It is estimated that approximately 50% of patients with hepatitis C virus (HCV) infection in Japan are currently over 75 years old. However, patients aged ≥ 75 years are typically underrepresented in clinical trials of direct-acting antivirals. This study aimed to evaluate the efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Komaki, Yuri, Ozono, Yoshinori, Nakamura, Kenichi, Iwakiri, Hisayoshi, Hasuike, Satoru, Sueta, Mitsue, Miike, Tadashi, Yamamoto, Shojiro, Uto, Hirofumi, Kusumoto, Kazunori, Ochiai, Toshimasa, Kato, Junya, Komada, Naoto, Kuroki, Kazuo, Eto, Toshiharu, Shigehira, Masafumi, Hirono, Shuichi, Nagata, Kenji, Kawakami, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052496/
https://www.ncbi.nlm.nih.gov/pubmed/35484503
http://dx.doi.org/10.1186/s12876-022-02284-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052496/
https://www.ncbi.nlm.nih.gov/pubmed/35484503
http://dx.doi.org/10.1186/s12876-022-02284-z

Ejemplares similares